Current management of diabetes patients with COVID-19

被引:2
|
作者
Misra, Arup Kumar [1 ]
Rangari, Gaurav [1 ]
Madhavrao, C. [1 ]
Sharma, Sushil [1 ]
机构
[1] All India Inst Med Sci AIIMS, Dept Pharmacol, Mangalagiri, Andhra Pradesh, India
关键词
COVID-19; diabetes mellitus; antidiabetic drugs; inflammation; infection; METFORMIN; GLUCOSE; INHIBITORS; MORTALITY; RECEPTOR; MUCORMYCOSIS; INFLAMMATION; PREVALENCE; MECHANISMS; THERAPY;
D O I
10.1080/17446651.2023.2187215
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionDiabetes mellitus (DM) and the 2019 coronavirus (COVID-19) appear to interact in both directions. There is mounting proof that patients with DM have a worse COVID-19 prognosis than those without it. Pharmacotherapy is also known to affect in view of the possible interplay between drugs and the pathophysiology of the above conditions in a given patient.Areas coveredIn this review, we discuss the pathogenesis of COVID-19 and its connections with diabetes mellitus. We also analyze the treatment modalities for COVID-19 and diabetes patients. The possible mechanisms of the different medications and their management limitations are also systematically reviewed.Expert opinionCOVID-19 management as well as its knowledge base is changing constantly. The Pharmacotherapy and the choice of drugs also need to be specifically considered in view of the concomitant presence of these conditions in a patient. Anti-diabetic agents must be carefully evaluated in diabetic patients in view of the disease's severity, blood glucose level, appropriate treatment, and other components that could aggravate adverse events. A methodical technique is anticipated to enable the safe and rational use of drug therapy in COVID-19-positive diabetic patients to take.
引用
收藏
页码:199 / 207
页数:9
相关论文
共 50 条
  • [41] Is Diabetes a Real Challenge in COVID-19 Patients?
    Jalal, Muhammed Jasim Abdul
    JOURNAL OF DIABETOLOGY, 2021, 12 (04) : 538 - 539
  • [42] Obesity and COVID-19 in Adult Patients With Diabetes
    Cao, Peihua
    Song, Ying
    Zhuang, Zian
    Ran, Jinjun
    Xu, Lin
    Geng, Yan
    Han, Lefei
    Zhao, Shi
    Qin, Jing
    He, Daihai
    Wu, Fengfu
    Yang, Lin
    DIABETES, 2021, 70 (05) : 1061 - 1069
  • [43] COVID-19 and Diabetes: will Novel Drugs for Diabetes Help in COVID-19?
    Al-kuraishy, Hayder Mutter
    Al-Gareeb, Ali Ismail
    Mostafa-Hedeab, Gomaa
    Dubey, Rupal
    Prabhakar, Pranav Kumar
    Batiha, Gaber El-Saber
    CURRENT MOLECULAR PHARMACOLOGY, 2023, 16 (04) : 494 - 506
  • [44] Pharmacological management of COVID-19 in type 2 diabetes
    Ceriello, Antonio
    Prattichizzo, Francesco
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (07)
  • [45] Myocarditis in COVID-19 patients: current problems
    Mele, Donato
    Flamigni, Filippo
    Rapezzi, Claudio
    Ferrari, Roberto
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (05) : 1123 - 1129
  • [46] Myocarditis in COVID-19 patients: current problems
    Donato Mele
    Filippo Flamigni
    Claudio Rapezzi
    Roberto Ferrari
    Internal and Emergency Medicine, 2021, 16 : 1123 - 1129
  • [47] COVID-19: Diabetes Perspective-Pathophysiology and Management
    Dallavalasa, Siva
    Tulimilli, SubbaRao V.
    Prakash, Janhavi
    Ramachandra, Ramya
    Madhunapantula, SubbaRao V.
    Veeranna, Ravindra P.
    PATHOGENS, 2023, 12 (02):
  • [48] COVID-19 and diabetes management: What should be considered?
    Ceriello, Antonio
    Stoian, Anca Pantea
    Rizzo, Manfredi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 163
  • [49] Diabetes burden and its management in covid-19 inpatients
    Neish, R.
    Blunt, T.
    Kurian, M.
    James, S.
    Kalathil, D.
    DIABETIC MEDICINE, 2022, 39
  • [50] Issues for the management of people with diabetes and COVID-19 in ICU
    Ceriello, Antonio
    Standl, Eberhard
    Catrinoiu, Doina
    Itzhak, Baruch
    Lalic, Nebojsa M.
    Rahelic, Dario
    Schnell, Oliver
    Skrha, Jan
    Valensi, Paul
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)